Balanced news tone
News Sentiment
GUTS sentiment intelligence
Fractyl Health, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
+4.0% over one week, -6.7% over four weeks, trend inactive, and below fair value.
H.C. Wainwright reiterates Buy on Fractyl Health stock at $8
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Fractyl Health (GUTS) director buys stock and receives 22,500 options
FRACTYL HEALTH, INC. director William Bradley reported an open-market purchase of 68,493 shares of Common Stock at approximately $0.7348 per share, increasing his direct holdings to 84,622 shares. Additionally, he received a grant of stock options for 22,500 shares with an exerci
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 21:08
- Source
- Stock Titan
Fractyl Health (NASDAQ: GUTS) director buys shares and receives options
Fractyl Health (NASDAQ: GUTS) director Ian Sheffield recently bought 35,000 shares of common stock at $0.7294 per share, bringing his direct holdings to 35,000 shares. Additionally, he was granted 22,500 stock options with an exercise price of $0.7318, set to vest in a single ins
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 11 Jun 2026 20:40
- Source
- Stock Titan
Fractyl Health (GUTS) director Marc Elia receives 22,500-share stock option grant
Fractyl Health (GUTS) director Marc Elia was granted stock options for 22,500 shares as compensation for his board service. The options have an exercise price of $0.7318 per share and will vest in a single installment, contingent on his continued service. Following this grant, El
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 20:40
- Source
- Stock Titan
Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let’s Look At Funding
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Market source
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- TradingView
Fractyl Health Says One-Year Data Shows Revita Sustains Post-GLP-1 Weight Loss
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 04 Jun 2026 12:14
- Source
- MT Newswires
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
- Tone
- Positive 58/100
- Event
- Earnings
- Published
- 04 Jun 2026 11:00
- Source
- GlobeNewswire
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 11:00
- Source
- GlobeNewswire
Nearly 1M leave GLP-1 therapy monthly; Fractyl hires market-access lead
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Stock Titan
UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+
- Tone
- Positive 84/100
- Event
- Earnings
- Published
- 26 May 2026 07:00
- Source
- eciks.org
Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 16 May 2026 07:00
- Source
- Market source
Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift – Has The Bull Case Changed?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 May 2026 07:00
- Source
- simplywall.st
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 13:19
- Source
- Simply Wall St.
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Quiver Quantitative
Fractyl Health Q1 Earnings Call Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- TradingView
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- GlobeNewswire
FRACTYL HEALTH ($GUTS) Releases Q1 2026 Earnings, Stock Rises | GUTS Stock News
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- Quiver Quantitative
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Fractyl Health CEO to speak at BofA conference after May 12 Q1 update
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Stock Titan
GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- StockStory
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 Apr 2026 07:00
- Source
- Seeking Alpha
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
H.C. Wainwright Maintains a Buy Rating on Fractyl Health, Inc. (GUTS) with an $8 Price Target
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 20 Mar 2026 07:00
- Source
- Market source
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- Market source
Fractyl Health (Nasdaq: GUTS) faces Nasdaq minimum bid-price warning
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 17 Mar 2026 07:00
- Source
- Stock Titan